3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Nasopharyngeal Carcinoma
10
Leukemia, Myeloid, Acute
4
Carcinoma, Non-Small-Cell Lung
4
Nasopharyngeal Neoplasms
3
Lung Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Rectal Neoplasms
2
Myelodysplastic Syndromes
2
Turcot syndrome
1
Tongue Neoplasms
1
Thrombocythemia, Essential
1
Rhabdoid Tumor
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoma
1
Locally Advanced Malignant Neoplasm
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Hypopharyngeal Neoplasms
1
Head and Neck Neoplasms
1
Esophagitis
1
Interventions
Trastuzumab
597
Paclitaxel
562
Cyclophosphamide
545
Docetaxel
479
Capecitabine
388
Letrozole
350
Fulvestrant
311
Doxorubicin
285
Carboplatin
277
Tamoxifen
257
Anastrozole
219
exemestane
211
Epirubicin
210
Radiotherapy
197
Bevacizumab
189
pertuzumab
177
Gemcitabine
163
Vinorelbine
162
pembrolizumab
161
Lapatinib
161
palbociclib
152
Exercise
132
Fluorouracil
118
Albumin-Bound Paclitaxel
116
eribulin
108
Magnetic Resonance Spectroscopy
108
130-nm albumin-bound paclitaxel
107
Everolimus
103
Taxes
96
Cisplatin
92
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Breast Neoplasms
×
Induction Chemotherapy
×
Clear all
NCT01491737
2020-10-28
PERTAIN
Hoffmann-La Roche
Phase 2
Completed
258 enrolled
18 charts